Drug Profile
Research programme: influenza virus therapeutics - Aus Bio
Alternative Names: MD 2009Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Aus Bio Limited
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in Australia
- 29 Oct 2012 Preclinical development is ongoing in Australia